Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
AssigneeOttawa Heart Institute Research Corporation
InventorsPeter Liu, Liyong Zhang
Life of this patent
Estimating the term…
Abstract
Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and/or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.
Claims17
A method for the treatment of heart failure in a subject in need thereof, said method comprising:
- administering an insulin-like growth factor-binding protein 7 (IGFBP7) inhibitor comprising a gene silencing nucleic acid targeting an IGFBP7 gene or an IGFBP7 mRNA in said subject to said subject to directly reduce IGFBP7 expression and/or activity levels in the heart of said subject,
- thereby treating heart failure in said subject.
A method for the treatment of heart failure in a subject in need thereof, said method comprising:
- administering an insulin-like growth factor-binding protein 7 (IGFBP7) inhibitor comprising an anti-IGFBP7 antibody to said subject to directly reduce IGFBP7 expression and/or activity levels in the heart of said subject,
- thereby treating heart failure in said subject.
A method for the treatment of heart failure in a subject in need thereof, said method comprising:
- administering an insulin-like growth factor-binding protein 7 (IGFBP7) inhibitor to said subject to directly reduce IGFBP7 expression and/or activity levels in the heart of said subject wherein the inhibitor is selected from a group consisting of a gene silencing nucleic acid directly targeting an IGFBP7 gene or an IGFBP7 mRNA and/or an anti-IGFBP7 antibody;
- and
- administering an insulin-like growth factor 1 receptor (IGF-1R) inhibitor comprising an anti-IGF-1R antibody to said subject to directly inhibit IGF-1R expression and/or activity levels in the heart of said subject;
- thereby treating heart failure in said subject.
Dependencies are inferred from the claim text.